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Introduction
Major advances in cancer treatment have been achieved in the 
past few decades. In addition to systematic approaches, such as 
immunotherapy, hormonal therapy, and chemotherapy, the devel-
opment of new cancer therapies is usually based on inhibition 
of disease-associated genes or signaling pathways (1), which is 
ascribed to the growing understanding of molecular mechanisms 
for cancer initiation and progression. Targeted therapy directly 
against those amplified or mutation-activated oncogenes, such 
as BCR-ABL, BRAF, or EGFR, has proven to be successful (2, 3), 
whereas the exploitation of tumor-suppressor mutations has 
lagged behind due to the difficulty of their functional restoration 
and mechanistic complexity. Synthetic lethality screens are one 
of the first developed approaches to targeting loss-of-function 
mutations or deletions in the tumor-suppressor genes (4–8). One 
notable example is the clinical success of poly ADP-ribose poly-
merase (PARP) inhibitors in treating breast and ovarian tumors 
carrying BRCA1 or BRCA2 mutations (8–10). Furthermore, PARP 
inhibitors also exhibit promising effectiveness in more common 
cancer types that possess mutations in the genes associated with 
DNA-damage response and double-stranded break (DSB) repair 
(11). However, few synthetic lethal interactions share the success 
of PARP inhibitors, although a large number of synthetic interac-
tions have been found. Obviously, the complexity of parameters 
in tumor and tumor microenvironment need to be determined for 
a synthetic lethal interaction from the cell-based screens before 
such an interaction is considered for translational therapeutics. 
Additionally, targeting synthetic lethal interactors is often unreli-
able in selectively killing tumor cells, as these lethal interactions 
do not perform essential functions and their inhibition can be res-
cued by complementary pathways.
We and others have proposed the concept of “essential lethali-
ty” as a strategy for identifying the unintended therapeutic vulner-
abilities that arise from these mutated or deleted essential genes 
(12–14). Their mutations are largely tolerated in cancer cells due 
to the fact that many essential cellular functions are carried out by 
several genes that share redundant functions. Further inhibition 
of their homologous or paralogous genes would be expected to 
exclusively eliminate tumor cells harboring those mutations while 
sparing normal cells that retain an intact genome. The principle 
of essential lethality builds up a foundation for the development 
of therapies resulting from tumor-suppressor gene deficiencies 
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tional redundancy between SA1 and SA2, WT SA1 is almost always 
retained in the SA2-mutated cancers. We reasoned that inactivat-
ing mutation of SA2 creates cancer-specific therapeutic vulner-
abilities, in which inhibition of SA1 would result in complete loss 
of cohesin activity and, consequently, cell death. We found that 
inhibition of SA1 in the SA2-deficient cells led to severe defects in 
chromatid separation and mitosis, followed by lethal failure of cell 
division. Moreover, depletion of SA1 sensitizes the SA2-deficient 
cancer cells to PARP inhibitors due to homologous recombination 
(HR) deficiency in DNA repair. Our study expands the concept of 
essential lethality to essential paralog genes bearing loss-of-func-
tion mutations and also provides a potential therapeutic approach 
for the SA2-deficient cancers.
Results
The SA2 gene is frequently mutated in human EWS and BUC. In a 
search of The Cancer Genome Atlas (TCGA; https://cancerge-
nome.nih.gov/) data sets for inactivating mutations of the essential 
paralog genes (24), we identified at least 10 candidates, which are 
listed in Supplemental Table 1 (supplemental material available 
online with this article; https://doi.org/10.1172/JCI98727DS1). 
SA2, which encodes a core subunit of the cohesin complex, is among 
the most commonly mutated genes across multiple cancer types 
(25, 26). The core complex of cohesin consists of 2 ATPase proteins 
(SMC1, SMC3), a “bridge” protein, and one of the 3 SA proteins in 
humans (21, 27). SA1 is ubiquitously expressed in all types of cells. 
SA2 on the X chromosome is robustly expressed, and its inactivat-
ing mutations on 1 allele result in complete null mutation due to X 
inactivation (28, 29). SA3 is expressed primarily in germinal cells 
(30). In somatic cells, SA1 and SA2 are mutually exclusive subunits 
of the cohesin complex that contain either SA1 or SA2, but never 
both (21, 27). Given the essential role of cohesion in the alignment 
and segregation of sister chromatids in mitosis, cancer cell–bear-
ing inactivating SA2 mutation was predicted to be highly sensitive 
to further inhibition of SA1, whereas the normal cell would not be 
affected due to the functional complementation of SA2.
Genomic analyses of TCGA found that SA2 is frequently mutat-
ed, in approximately 15% of EWS (31, 32) and BUC (33–35); most 
of these mutations (82%, 24 out of 29 EWSs; 69%, 30 out of 44 
BUCs) are truncating mutations that lead to complete loss of SA2 
expression (Figure 1, A and B). Notably, we observed a mutually 
exclusive mutation pattern between SA1 and SA2, and WT SA1 was 
almost always retained in the context of SA2 mutation (Figure 1C 
and Supplemental Figure 1, A and B). Furthermore, their functional 
redundancy was supported by the inverse correlation between the 
expression levels of these 2 proteins in 179 human BUC tissue sam-
ples (P = 0.002, Figure 1, D and E; Supplemental Figure 1, C and D). 
A compensatory increase of SA1 was observed in the SA2-mutated 
cell lines, whereas abundant expression of SA3 was only observed in 
germinal cells (Figure 1F and Supplemental Figure 1, E–G).
Depletion of SA1 inhibits the growth of SA2-mutated tumors. We 
carried out shRNA-mediated depletion of SA1 in a panel of SA2-
mutated (EW8, TC32, UC3, and UC14) and SA2-intact (A673, TC71, 
RT4, and T24) cells. Specifically, the expression of doxycycline-
induced (Dox-induced) SA1 shRNA led to markedly reduced pro-
liferation in SA2-mutated cells in comparison with that of the cor-
responding cells expressing control shRNA (Figure 2, A and B, and 
(15–18). Muller and colleagues showed that the inhibition of gly-
colytic gene enolase 2 (ENO2) selectively suppresses growth and 
tumorigenic potential of glioblastoma cells carrying homozygous 
deletion of ENO1 (13). In an integrated analysis of genome-wide 
copy number alterations and RNA inhibition databases, the Hahn 
group identified as many as 56 copy number alterations yielding 
cancer liabilities owing to partial loss (CYCLOPS) genes as poten-
tial cancer-specific vulnerabilities (14). As a proof of concept, they 
showed that cancer cells harboring partial deletion of PSMC2 are 
sensitive to further suppression of PSMC2 by RNA interference. 
Most genetic alterations are the result of increased genomic insta-
bility in cancer, but do not contribute to tumor development (19). 
In particular, copy number losses that target tumor-suppressor 
genes frequently involve multiple neighboring essential genes that 
may not contribute to cancer development. The loss of such essen-
tial genes has been postulated as rendering cancer cells highly 
vulnerable to the further suppression or inhibition of these genes 
(14). Our recent studies revealed that focal deletion of TP53 often 
encompasses POLR2A, a neighboring essential gene that encodes 
the largest subunit of the RNA polymerase II (Pol II) complex 
(12, 20). Because RNA Pol II is in charge of mRNA synthesis and 
indispensable for cell survival, complete knockout of POLR2A is 
lethal to any cells. Although hemizygous (or partial) loss of TP53/
POLR2A has a minimal impact on cell proliferation and survival, it 
creates a therapeutic vulnerability in cancer cells containing such 
genomic defects. We found that suppression of POLR2A expres-
sion by α-amanitin (a highly specific inhibitor of the RNA Pol II) 
selectively inhibits proliferation, survival, and tumorigenic poten-
tial of colorectal cancer cells with hemizygous loss of TP53.
Mitosis is a critical process in cell proliferation. Cohesion 
between sister chromatids needs to be maintained until chromo-
some segregation as the cell transitions from late metaphase into 
early anaphase. In physical association with chromosome, cohesin 
is a multisubunit protein complex that mediates cohesion between 
replicated sister chromatids and is thus essential for cell proliferation 
(21). In mammalian cells, the canonical cohesin complex is com-
posed of 4 components, including 2 structural maintenance of chro-
mosome (SMC) subunits (SMC1α/β and SMC3), 1 stromalin, 1 klei-
sin subunit, and stromal antigen (SA, also known as STAG) protein. A 
wide variety of cohesin complexes are formed with diverse key com-
ponents and their regulatory proteins in mitotic cells. Besides their 
functions in chromosome segregation, these cohesin complexes are 
also important for DNA damage response, DNA repair, and genome 
integrity. Germline mutations in primary genes associated with 
the cohesin network lead to a group of human diseases termed as 
cohesinopathies, which are identified as multisystem developmental 
disorders with distinct phenotypes (22). For example, a dominantly 
inherited disease, Cornelia de Lange syndrome, is caused by point 
mutations or small deletions/insertions in 1 of the 2 alleles of SMC1, 
SMC3, or NIPBL (encoding a cohesion-loading factor). Defects in the 
cohesion complex are proposed to generate aneuploidy and genomic 
instability, which eventually result in tumorigenesis. Heterozygous 
knockout of SA1 in mice drives aneuploidy and results in an increased 
risk of cancer due to impaired replication of telomeres (23).
In this study, we analyzed human cancer genomes and uncov-
ered frequent mutations of the SA2 gene in Ewing sarcoma (EWS) 
and bladder urothelial carcinoma (BUC). Consistent with the func-
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and UC3 cells (Supplemental Figure 2, D and E). To exclude genetic 
difference across cell lines, we used the CRISPR/Cas9 system to 
generate isogenic TC71 and RT4 cell lines carrying inactivating 
mutations of SA2 (Supplemental Figure 3, A–D). To recapitulate the 
most frequent patient-derived mutations, we generated the isogen-
ic cell lines bearing R216* or Q593* that disrupt SA2 expression due 
to early stop codon (Supplemental Figure 3, B and C). Isogenic SA2-
Supplemental Figure 2, A and B). Despite significant knockdown 
(KD) of SA1, the SA2-intact cells (TC71 and RT4) continued to pro-
liferate, whereas the SA2-mutated cells (TC32 and UC3) exhibited 
severe apoptosis (Figure 2C). In direct competition assays, stable 
KD of SA1 led to markedly reduced proliferation in UC3 cells, but 
not in RT4 cells (Supplemental Figure 2C). The effects of SA1 silence 
were rescued by ectopic expression of SA2 in the SA2-mutated TC32 
Figure 1. SA2 is frequently mutated in EWS and BUC. (A) Frequencies of SA2 mutation in a variety of human cancers. UCS, uterine carcinosarcoma; ACbC, 
adenoid cystic carcinoma of the breast. (B) The nature of SA2 alterations in all EWS (left) and BUC (right) data sets as listed in A. (C) Genomic alterations 
of SA1 and SA2 in EWS and BUC data sets as listed in A and in 15 other pan-cancer data sets in TCGA. (D and E) Negative correlation between SA1 and SA2 
expression levels (D, Fisher’s exact test) and their representative immunohistochemical images (E) in human BUC samples and adjacent normal controls. 
Scale bars: 50 μm. (F) Protein levels of SA1 and SA2 in human EWS and BUC cell lines, determined by immunoblotting. β-Actin was used as a loading 
control. Experiments were conducted 3 times for validation.
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ration (PCS), but it only had modest effects on the SA2-intact cells 
(TC71 and RT4) (Figure 4, A and B) and normal primary mesenchy-
mal stem cells (MSCs) (Supplemental Figure 5, A–C). Furthermore, 
the SA2-mutated TC32 cells displayed a significantly increased 
mitotic fraction and an induced cell population with 4N DNA con-
tent, characteristic of mitotic failure (Figure 4C and Supplemental 
Figure 5, D and E). Using time-lapse microscopy, we analyzed the 
mitotic fates as the cell progressed through mitosis from nuclear 
envelop breakdown (NEB) to anaphase or cell death. Depletion of 
SA1 led to a dramatic extension of the mitotic duration in the iso-
genic SA2-mutant TC71 cells, but not their parental cells, which is 
strongly correlated with mitotic catastrophe and cell death (Figure 
4, D–F). In line with these observations, RNA-sequencing (RNA-
seq) and gene ontology (GO) enrichment analyses showed that 
depletion of SA1 led to negative enrichment of cell-cycle and chro-
mosome segregation pathways in the SA2-mutated TC32 cells, but 
not in the SA2-intact TC71 cells (Figure 4, G and H).
SA1 inhibition renders the SA2-mutated cancer cells vulnerable to 
DSB. We next analyzed the genome-wide gene expression profiles 
to systematically identify transcriptome reprogramming in the 
SA2-mutated cells. GO enrichment analyses of the SA2-mutat-
mutated cells exhibited proliferation rates similar to those of their 
parental cells, but KD of SA1 in these cells significantly inhibited 
their proliferation (Supplemental Figure 3, D–G). Moreover, Dox-
induced SA1 shRNA inhibited the growth of SA2-mutated tumors 
derived from EWS (TC32) (Figure 3, A–C) and BUC (UC3) (Figure 3, 
D–F) cells in vivo, and correspondingly, these tumors had a marked 
reduction in cell proliferation (as measured by Ki-67 levels) and a 
significant increase in cell apoptosis (as measured by cleaved cas-
pase-3 levels) (Supplemental Figure 4, A–F). However, SA1 deple-
tion only had a modest effect on tumor growth of the SA2-intact 
tumors (TC71 and RT4) (Figure 3, A–F, and Supplemental Figure 
4, A–F). These in vivo results confirmed that the paralogous SA1 is 
essential in the SA2-mutated tumors.
Inhibition of SA1 in SA2-mutated cells leads to lethal failure of 
cell division. Given the fundamental role of cohesion during mito-
sis (21, 27), we postulated that the combined depletion of SA1 and 
SA2, in contrast with the loss of either one alone, could severely 
impair cell division. We observed that depletion of SA1 selectively 
abolished the alignment and separation of sister chromatids in the 
SA2-mutated cells (TC32 and UC3), leading to the formation of 
railroad chromosomes (RR) and premature sister chromatid sepa-
Figure 2. Depletion of SA1 inhibits the growth of SA2-mutated cells in vitro. (A and B) Cell growth curve, based on crystal violet staining, of EWS (A) and 
BUC (B) cell lines expressing Dox-inducible control shRNA (shNT) or SA1-specific shRNA (shSA1). (C) Fraction of apoptotic cells in the SA2-intact (TC71, 
RT4) and SA2-mutated (TC32, UC3) cell lines expressing Dox-induced shSA1 for 4 days. *P < 0.05; **P < 0.01. One-way ANOVA followed by Tukey’s t test (A 
and B) and unpaired 2-tailed t test (C) were performed to compare different groups. Data are presented as mean ± SD and are representative of 3 indepen-
dent experiments. Ctrl, control.
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duration of γ-H2AX foci in the SA2-mutated RT4 and TC71 cells 
(Figure 6, B and C, and Supplemental Figure 6D). Together, these 
data suggest that SA2-mutated cancer cells, upon depletion of SA1, 
are not only more susceptible to DNA damage, especially DSBs, 
but are also defective in DNA repair.
SA1 inhibition sensitizes SA2-mutated cancer cells to the treat-
ment of PARP inhibitors. Treatment of PARP inhibitors causes 
failure of single-strand break (SSB) repair, which can lead to DSBs 
when DNA replication forks stall and collapse at persistent SSB 
lesions (37–39). In particular, the marked sensitivity of EWS cells 
harboring EWS-FLI1 to PARP inhibitors was first identified in a 
systematic screen for genomic markers that determine drug sensi-
tivity in cancer cells. We performed dose-response experiments to 
measure the cytotoxicity of 3 PARP inhibitors (veliparib, olaparib, 
and BMN-673) in a panel of SA2-intact and -mutated cell lines (40). 
KD of SA1 in the SA2-mutated (R216*) RT4 cells led to remarkably 
dampened cell survival and increased apoptosis in the presence of 
olaparib and BMN-673 (Figure 7, A and B, and Supplemental Fig-
ure 7A). Moreover, the SA2-mutated cells (TC32 and UC3), upon 
depletion of SA1, were more sensitive to olaparib, but not cispla-
tin treatment, showing a synergistic effect with a combination 
index (CI) of less than 0.5 (Figure 7C and Supplemental Figure 
7B). Notably, combined treatment with SA1 depletion and PARP 
ed cells in the presence of SA1 inhibition demonstrated distinct 
expression patterns characterized by a marked decrease in canoni-
cal pathways associated with DSB repair, HR, and DNA damage 
checkpoint control (Figure 5, A and B). Because this feature was 
in line with an increased transcription-based HR-defective (HRD) 
score (ref. 36, Figure 5C, and Supplemental Figure 6, A and B), we 
reasoned that SA2-mutated cells, upon depletion of SA1, could 
be susceptible to PARP inhibitors due to their defective HR DNA 
repair. As expected, KD of SA1 dramatically inhibited HR repair 
efficacy in the SA2-mutated TC32 and UC3 cells, in contrast with 
the SA2-intact TC71 and RT4 cells (Figure 5D). To monitor DNA 
damage in individual cells, we performed a single-cell neutral 
comet assay and found that the basal level of DSB (measured by 
tail moments) was notably elevated in the SA2-mutated cells with 
SA1 KD (Figure 6A and Supplemental Figure 6C). While irradia-
tion (IR) significantly increased the levels of DSB in both SA2-
intact and -mutated cells, DSB levels were reduced to a level close 
to the basal level in the SA2-intact cells (TC71 and RT4), but not in 
the SA2-mutated cells (TC32 and UC3) at 12 hours after IR (Figure 
6A). We also examined the effect of SA1 depletion on the tempo-
ral dynamics of γ-H2AX foci, another indicator for DSB. While it 
had a minimal effect on the number of γ-H2AX foci in the paren-
tal cells, the SA1 depletion profoundly increased the number and 
Figure 3. Depletion of SA1 impairs the growth of SA2-mutated tumors in vivo. (A–C) Tumor growth curves (A), representative bioluminescent images 
(B), and gross tumor weights (C) of xenograft tumors derived from orthotopically implanted (left intratibial injection) EWS TC71 and TC32 cells express-
ing Dox-inducible SA1 shRNA (n = 5). No tumor indicates the corresponding right lower leg without tumor implantation. (D–F) Tumor growth curves (D), 
gross tumor images (E), and weights (F) of xenograft tumors derived from subcutaneously implanted BUC cells RT4 and UC3 expressing Dox-inducible SA1 
shRNA (n = 5). **P < 0.01; ***P < 0.001 versus control by unpaired 2-tailed t test. Data are presented as mean ± SD.
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inhibitor had a minimal effect on normal primary MSC (Supple-
mental Figure 7, C–E). Cohesion defect analysis revealed a striking 
increase of PCS upon combined treatment with SA1 depletion and 
BMN-673 in the SA2-mutated cells (Figure 8A and Supplemental 
Figure 7F). Analysis of mitotic chromosome segregation by time-
lapse fluorescence microscopy showed that SA1 depletion alone in 
the SA2-mutated cells resulted in a higher percentage of mitoses 
that lose chromosome alignment on the metaphase plate, a pro-
cess termed as chromosome scattering. This cohesion defect was 
further aggravated when the treatment was combined with BMN-
673, leading to a much prolonged mitotic arrest and thereafter 
massive mitotic catastrophe and cell death (Figure 8, B and C, and 
Supplemental Figure 7G).
SA1 inhibition sensitizes SA2-mutated tumors to the treatment 
of PARP inhibitor BMN-673. Based on the synergy of SA1 deple-
tion and PARP inhibition, we investigated the efficacy of the 
combined treatment in SA2-mutated tumors in vivo. Mice bear-
ing TC32-derived tumors expressing luciferase were random-
ized and treated with vehicle and nonspecific RNA control, SA1 
siRNA (500 μg/kg, twice per week), BMN-673 (0.33 mg/kg, once 
daily), or a combination of SA1 siRNA and BMN-673. Consistent 
with the results in vitro, treatment with SA1 siRNA or BMN-673 
alone had limited effects, whereas their combinatorial treat-
ment resulted in a significant suppression of tumor growth and 
an extension of mouse survival. Complete tumor regression was 
observed in 11 out of 13 mice from the combined treatment group 
(Figure 9, A–C). In addition, we also tested the antitumor activity 
of the combinatorial treatment in orthotopic BUC tumors derived 
from UC3 cells. siRNA-mediated SA1 depletion alone significant-
ly inhibited tumor growth, which was further intensified when 
the treatment was combined with BMN-673, leading to complete 
tumor regression (12 out of 15 mice) (Figure 9, D–F). Correspond-
ingly, these tumors exhibited a marked reduction in cell prolif-
eration and a significant increase in cell apoptosis (Figure 9G and 
Supplemental Figure 8, A–D). The combinatorial treatment had 
no notable toxicity in vivo, as reflected by negligible body weight 
changes (Supplemental Figure 8, E and F). In contrast, there was 
no or limited synergistic effects of combinatorial treatment on 
tumor growth of the SA2-intact tumors (TC71 and RT4), although 
BMN-673 treatment alone resulted in modest tumor inhibition 
(Supplemental Figure 9). Collectively, these results demonstrate 
that inhibition of SA1 sensitizes the SA2-mutated tumors to the 
treatment of PARP inhibitors.
Discussion
Due to the limited number of genomic mutations, targeted cancer 
therapies have yet to succeed in clinical applications for EWS and 
BUC. The oncogenic phenotype of EWS is primarily driven by one 
underlying prototypical chromosomal translocation, fusion of the 
EWS gene on chromosome 22q24 with 1 of 5 E–twenty-six (ETS) 
transcription factor gene family members (FLI, ERG, ETV1, E1AF, 
and FEV). Of the EWS/ETS translocations, a majority of Ewing’s 
tumors harbor the EWS/FLI reciprocal translocation (41). Howev-
er, targeting oncogenic transcription factors such as EWS/FLI has 
proven to be problematic due to their lack of intrinsic enzymatic 
activity and poor druggability. In the clinical trials for treating BUC, 
a number of inhibitors against EGFR, FGH receptor (FGHR), and 
human epidermal growth factor receptor 2 (HER2) have shown very 
limited activity as single agents or when combined with other thera-
peutic agents (42). Therefore, there is a great need to develop new 
therapeutic approaches to targeting specific genomic alterations in 
both types of cancer. Inactivating mutation of SA2 in EWS and BUC 
creates therapeutic vulnerability to the inhibition of SA1.
Recent progress in cancer genomics enables the identification 
of potential therapeutic targets from genomic alterations that have 
been long ignored due to their classification as nondriver muta-
tions (20, 43). Paralog dependency is a new approach to identify-
ing essential genes that are functionally required in the context 
of paralog gene deficiency. In this study, SA1 is identified as an 
essential gene in human cancers carrying inactivating mutations of 
SA2. SA2 and other recurrent alterations in subunits of the cohesin 
complex have been reported across a number of cancer types (21, 
27, 44–46), which are assumed to abrogate chromosomal segrega-
tion, leading to increased chromosomal translocation and aneu-
ploidy. However, a low rate of aneuploidy and genomic instability 
was often observed in the SA2-mutated cancers, including EWS, 
BUC, and myeloid neoplasms (47, 48). Therefore, biological con-
sequences as well as clinical relevance remain to be clarified con-
cerning SA2 and other cohesin-associated mutations. A significant 
intersection of SA2 mutation with alteration of the p53/p21 path-
way was observed in EWS (49), suggesting that this genomic event 
may coordinate with other genomic alterations in tumorigenesis.
Inhibition of SA1 as a potential therapeutic approach was first 
suggested in cell-based studies (50, 51). However, all the vari-
ables and complexity of the in vivo tumor environment need to 
be considered before this approach can be considered for further 
therapeutic translation. To address the potential problems of irre-
producibility in cell culture, the synthetic lethal interaction needs 
to be validated in vivo to determine whether a large therapeutic 
window exists. To better evaluate the in vivo tumor inhibition by 
the depletion of SA1, we established orthotopic tumor models in 
both EWS and UBC studies. Our results not only validate SA1 as 
a therapeutic target, but also identify SA1 inhibition as a promis-
ing approach to optimizing the PARP inhibitor–based therapies 
that are being rapidly developed for a wide array of human cancers. 
The previously reported sensitivity of EWS cells harboring EWS-
FLI1 to PARP inhibitors was based on a screen for the correlation 
Figure 4. Depletion of SA1 in SA2-mutated cells leads to lethal mitotic 
retardation and failure. (A and B) Quantification of cohesion defects (A) 
and representative metaphase images (B) in EWS and BUC cells expressing 
Dox-inducible control shNT or SA1-specific shSA1. (C) Cell-cycle analysis 
of the SA1-depleted TC71 and TC32 cells by costaining with DAPI and 
phospho–histone H3. (D) Duration of mitosis in parental and isogenic SA2-
mutated TC71 cells expressing Dox-induced control shNT or SA1-specific 
shSA1. Cells were synchronized with double-thymidine block and measured 
by differential interference contrast (DIC) microscopy time-lapse imaging 
for 48 hours after release. (E and F) Under each condition as described 
above, 50 cells were analyzed. Quantification of mitotic fates is shown in 
E. KD efficiency of shSA1 in TC71 cells is shown in F. (G and H) Negative 
enrichment of cell-cycle (G) and chromosome segregation (H) gene sets 
following SA1 KD in the SA2-mutated TC32 cells as determined by GO 
enrichment analysis. *P < 0.05; **P < 0.01, Fisher’s exact test (A and E) 
and unpaired 2-tailed t test (C and D). Data are presented as mean ± SD 
and are representative of 3 independent experiments (A–F).
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TC71 and A4573 were obtained from the Characterized Cell Line 
Core Facility (MD Anderson Cancer Center). TC32 and EW8 cell lines 
were provided by Joseph A. Ludwig (MD Anderson Cancer Center). 
Cell lines were banked in multiple aliquots on receipt to reduce risk of 
phenotypic drift. Cell identity was confirmed by validating STR DNA 
fingerprinting using the AmpFLSTR Identifiler Kit according to the 
manufacturer’s instructions (Applied Biosystems).
Anti-SA1 (HPA035015), anti-SA2 (HPA002857), and anti-SA3 
(HPA049106) antibodies were purchased from Sigma-Aldrich. Anti–
Ki-67 (D3B5), anti–cleaved caspase-3 (Asp175, 5A1E), and anti–phos-
pho–histone H2AX (Ser139, 20E3) antibodies were obtained from 
Cell Signaling Technology. Anti–β-actin (sc-1616), HRP–anti-goat IgG, 
where HRP indicates horseradish peroxidase (sc-2020), HRP–anti-
rabbit IgG (sc-2054), and HRP–anti-mouse IgG (sc-2055) antibodies 
were purchased from Santa Cruz Biotechnology Inc. Cell lysate prepa-
ration, SDS-PAGE, and Western blotting were performed as previ-
ously described (53). See complete unedited blots in the supplemental 
material. The PARP inhibitors olaparib, veliparib, and BMN-673 were 
purchased from Selleckchem.
shRNA-mediated KD of SA1. SA1-specific shRNA clones were 
obtained from the MD Anderson shRNA and ORFeome Core Facil-
ity (originally from Open Biosystems). Four SA1-targeting shRNAs 
were screened. Only 2 of these shRNAs knocked down the level of 
between genomic markers and drug sensitivity in cell lines (40). 
While notable sensitivity of 2 EWS cell lines (TC71 and TC32, both 
harboring EWS-FLI1) to the PARP inhibitor was observed in vitro, 
the treatment of BMN-673 had minimal inhibition on the growth 
of TC32-derived tumors in vivo (52). Mutations on BRAC1/2 or 
on those genes that promote “BRCAness” have not been found in 
global analyses of EWS and BUC cancer genomes. Consistently, 
the SA2-mutated tumors appeared to have little difference in their 
sensitivity to the PARP inhibitors that were tested as single agents 
in this study, in comparison with the SA2-intact tumors. However, 
systematic analyses of gene expression profiles revealed that inhib-
iting SA1 in the SA2-mutated tumors dramatically increased their 
susceptibility to the PARP inhibitors due to their defects in HR 
repair and cell-cycle checkpoint. Further advances in the devel-
opment of SA1 inhibitors, along with the integration of functional 
markers of SA2 mutation, have the strong potential to extend the 
utility of PARP inhibitor–based therapies.
Methods
Cell culture, antibodies, and Western blot analysis. 5637, HT1197, RT4, 
T24, UM-UC-3, A673, SK-ES-1, and HUVEC cell lines were obtained 
from ATCC and cultured under standard conditions specified by the 
manufacturer. UM-UC-14 was purchased from Sigma-Aldrich, and 
Figure 5. SA2-mutated cancer cells, upon depletion of SA1, are defective in HR. (A) Negative enrichment of the DNA repair gene set in the SA1-KD TC32 
cells, determined by GO enrichment analysis. (B) Venn diagram showing overlaps of dysregulated DNA repair genes in the SA1-KD TC32 cells with the HRD 
gene signature. (C) Heatmap of clusters indicates that TC32 cells had increased levels of HRD upon SA1 KD, as analyzed by unsupervised clustering for HRD 
gene signature genes. (D) The SA2-mutated cancer cells are defective in the HR repair. Modified HR repair assay was performed by transfecting cells with 
DR-GFP DSB substrate and I-Sce I plasmids, and flow cytometry analysis was performed to detect GFP-positive cells. **P < 0.01; ***P < 0.001, Fisher’s 
exact test (B) and unpaired 2-tailed t test (D). Data are presented as mean ± SD and are representative of 3 independent experiments (D).
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with uninfected RFP-negative cells at a ratio of 1:1 and cultured for 6 
passages. The numbers of RFP-positive and total cells on each passage 
were analyzed and quantified by flow cytometry, and the percentages 
of RFP-positive cells were calculated.
Cell proliferation and survival assay. Equal numbers of cells were 
plated in 12-well plates in triplicate. Cells were fixed with 1% formal-
dehyde/methanol and stained with 0.1% crystal violet. After staining, 
wells were washed 3 times with PBS and destained with acetic acid. 
Absorbance of the crystal violet solution was measured at 590 nm. In 
cell-survival assay, cells were seeded at a concentration of 1,000 cells 
per well in 96-well plates and treated with Dox (2 μg/ml) or indicat-
ed PARP inhibitors for 4 to 7 days. Cell viability was quantified using 
WST-1 reagent (Roche) according to the manufacturer’s instructions. 
All experiments were performed in triplicate.
Apoptosis and cell-cycle analysis. Cells were treated with Dox or 
PARP inhibitors for indicated time points and stained with annexin 
V–APC and SYTOX Blue (Thermo Fisher). Apoptosis was analyzed 
by flow cytometry using BD FACSARIA III Flow Cytometer (BD Bio-
sciences) according to the manufacturer’s protocol. Both apoptotic 
(annexin V positive and SYTOX blue negative) and dead (annexin 
V positive and SYTOX blue positive) cells were included in the 
analyses. For cell-cycle analysis, cells were fixed in ice-cold 70% 
SA1 protein by at least 60%–80% in all the EWS and BUC cell lines 
tested. The clone identification numbers and shRNA sequences 
were V3LHS_325808 (5′-AGAACATCTGATTCTACGT-3′) and 
V3LHS_325809 (5′-GAAGTAGTAACTCCAACCT-3′). The hairpin 
sequences in the GIPZ vector were cloned into the TRIPZ vector 
(Dharmacon) using a protocol provided by the manufacturer. The 
TRIPZ vector is a Dox-inducible system with a red fluorescent protein 
(RFP) reporter, and single colonies with robust SA1 KD (>80%) were 
chosen for the downstream experiments.
Quantitative RT-PCR. Total RNA was isolated using Direct-zol RNA 
extraction kit (Zymo Research) and then reverse-transcribed (RT) using 
qScript cDNA SuperMix Kit (Quantabio). The resulting cDNA was used 
for quantitative PCR using PerfeCTa SYBR Green SuperMix (Quanta-
bio) with gene-specific primers, and the results were normalized with 
β-actin as a control. PCR primers are listed in Supplemental Table 2. Ct 
values were calculated using ROX normalization.
Competition assay using SA1 shRNA. RT4 and UC3 cells were 
infected with control shNT or SA1 shRNA–expressing lentiviruses 
(pTRIPZ backbone) at a MOI of 2. Two days after infection, Dox-
induced RFP-positive cells were sorted using a BD FACSJazz Cell 
Sorter (BD Biosciences) at the MD Anderson Flow Cytometry and 
Cellular Imaging Core Facility. Next, RFP-positive cells were mixed 
Figure 6. SA2-mutated cancer cells, upon depletion of SA1, are defective in IR-induced DSB repair. (A) Effect of SA1 KD on IR-induced DNA damage repair 
determined by neural comet assay. Cells with or without siRNA against SA1 (siSA1) KD were treated with 5 Gy of IR and then subjected to neutral comet 
analysis at the indicated time points. Nontarget siRNA (siNT) was used as negative control. (B) Micrographs of parental and isogenic SA2-mutated RT4 
cells with or without SA1 KD. Cells were stained for γ-H2AX following 5 Gy IR treatment at the indicated time points. (C) Histograms show the number of 
γ-H2AX foci per cell as described above. **P < 0.01; ***P < 0.001, unpaired 2-tailed t test. Data are presented as mean ± SD and are representative of 3 
independent experiments.
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acquired every 10 minutes at 37°C using an IncuCyte live-cell imaging 
system (Essen BioScience). Images were processed using ImageJ soft-
ware (NIH) and analyzed using the mitotic duration plugin.
HR repair analysis. The HR and SSA repair assays were performed 
as described previously (55–58). To examine the role of SA1 depletion 
in DSB repair, cells were pretreated with or without Dox (2 μg/ml) for 
48 hours and then transfected with plasmids expressing I-SceI for 48 
hours. Cells transfected with an empty vector were used as a negative 
control. GFP-expressing plasmid (pEGFP-C1) was used for transfec-
tion efficiency control. Flow cytometry analysis was performed to 
detect GFP-positive cells using BD LSR Fortessa (BD Biosciences) 
with FlowJo software. The repair efficiency was scored as the percent-
age of GFP-positive cells.
Neutral comet assay. The neutral comet assay was performed 
using the CometAssay Kit (Trevigen) according to the manufacturer’s 
instructions. Briefly, following IR, cells were harvested and mixed 
with agarose with low melting temperature as single-cell suspensions 
at 37°C. The resulting cell/agarose mixture was immediately layered 
onto comet assay slides. The agarose was allowed to set for 1 hour at 
4°C, and cells on the slides were then lysed at 4°C for 30 minutes in 
the dark. After lysis, the slides were subjected to electrophoresis and 
then immersed twice in distilled water for 10 minutes and once in 70% 
(v/v) ethanol for 5 minutes. The slides were then dried completely at 
room temperature and stained with SYBR Green I (Trevigen). Comets 
ethanol. Cells were incubated with rabbit anti–pS10–histone H3 
(D7N8E, Cell Signalling) for 1 hour and with Alexa Fluor 488 goat 
anti-rabbit (Thermo Fisher) for 30 minutes. Cells were washed and 
resuspended in PBS with 1:10 DAPI (Thermo Fisher)/RNase stain-
ing buffer (BD Biosciences) and analyzed by flow cytometry on a BD 
LSR Fortessa (BD Biosciences). Cell-cycle analysis was conducted 
using FlowJo software.
Cohesion-defect analysis. Cohesion-defect analysis was performed 
as previously described (54). To enrich for mitotic cells, the medium 
was supplemented with 330 nM nocodazole for 4 hours. Cells were 
harvested by mitotic shake-off and centrifugation. Subsequently, 
cells were incubated with 200 ng/ml demecolcine (Sigma-Aldrich) 
in medium for 20 minutes, harvested, resuspended in 75 mM KCl 
for 20 minutes, and fixed in methanol/acetic acid (3:1). Cells were 
dropped onto glass slides and stained with 5% Giemsa (Merck); cohe-
sion defects were microscopically analyzed. Under each condition, 50 
metaphases per slide were counted on 2 coded slides as technical rep-
licates. Chromosome spreads from individual cells were classified and 
scored with regard to the status of sister chromatid cohesion based on 
the indicated morphological criteria.
Time-lapse microscopy. To quantify mitotic duration and cell-divi-
sion status, cells were synchronized with a double-thymidine block 
and, after 8-hour release, were seeded in 12-well plates. Phase con-
trast images of cells with stable RFP-H2B expression and SA1 KD were 
Figure 7. SA1 depletion sensitizes SA2-mutated cells to the treatment of PARP inhibitors. (A and B) SA1 depletion sensitizes the SA2-mutated RT4 cells 
to the treatment of PARP inhibitors. Representative images (A) and quantitative results (B) of cell survival are shown. Parental and isogenic SA2-mutated 
RT4 cells expressing control or SA1 siRNA were treated with indicated PARP inhibitors for 72 hours. (C) Dose-dependent responses of the SA2-intact or 
-mutated cell lines to the treatment of olaparib (72 hours) with or without SA1 KD. **P < 0.01; ***P < 0.001; ****P < 0.0001, unpaired 2-tailed t test. Data 
are presented as mean ± SD and are representative of 3 independent experiments.
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Liposomal nanoparticle preparation. SA1 siRNAs for in vivo delivery 
were encapsulated into neutral 1,2-dioleoyl-sn-glycero-3- phosphati-
dylcholine–based (DOPC-based) liposomes as previously described 
(12). DOPC and siRNA were mixed in the presence of excess tertiary 
butanol at a ratio of 1:10 (w/w) siRNA/DOPC. Tween 20 was added 
to the mixture in a ratio of 1:19 Tween 20/siRNA-DOPC. The siRNA 
sequences were as follows: control siRNA (5′-UUCUCCGAACGUGU-
CACGU-3′ and 5′-ACGUGACACGUUCGGAGAA-3′); STAG1 siRNA 
no. 1 (5′-GAAAUUGGAGUAUGGAUGA-3′ and 5′-UCAUCCAUA-
CUCCAAUUUC-3′); and STAG1 siRNA no. 2 (5′-GACAGUUCAUU-
CAUACCUA-3′ and 5′-UAGGUAUGAAUGAACUGUC-3′). The mix-
ture was vortexed, frozen in an acetone/dry-ice bath, and lyophilized. 
Before in vivo administration, this preparation was hydrated with PBS 
were observed and recorded by a Leica DM4B fluorescence micro-
scope and analyzed with CometScore (TriTek). The olive tail moment 
was determined by scoring 100 cells in each sample.
Immunofluorescence staining. Immunofluorescence staining and 
imaging were performed as previously described (55). Briefly, cells were 
cultured on chamber slides and treated with 5 Gy IR. At different times 
following IR treatment, cells were washed with PBS, fixed with 4% para-
formaldehyde at room temperature for 10 minutes, blocked with 5% 
normal horse serum for 30 minutes, and probed with anti–γ-H2AX anti-
body (Cell Signalling) at 4°C overnight and secondary antibody Alexa 
Fluor 594–conjugated goat anti-rabbit IgG for 1 hour at room tempera-
ture. The slides were washed and incubated with DAPI for 2 minutes in 
the dark and then analyzed with a fluorescent microscope.
Figure 8. Combined treatment with SA1 depletion and PARP inhibitor in SA2-mutated cells aggravates cohesion defects. (A) Quantification of cohesion 
defects in UC3 cells expressing Dox-induced control shRNA or shSA1 with or without BMN-673 (10 nM) treatment. (B, C) Percentages of mitotic fates (B) in 
UC3 cells after combined treatment with Dox-induced SA1 KD and BMN-673 (10 nM). The representative images for each type of mitotic fate are shown in 
C. **P < 0.01; ***P < 0.001, Fisher’s exact test. Data are presented as mean ± SD and are representative of 3 independent experiments.
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in 100 μl growth medium (mixed with Matrigel at 1:1) were injected 
subcutaneously into the flank using a 1 ml syringe (Fisher Scientific). 
Tumor size was measured twice a week using a caliper, and tumor vol-
ume was calculated using the standard formula: 0.5 × L × W2, where L 
is the longest diameter and W is the shortest diameter.
For the orthotopic EWS mouse model, the NU/J mice were 
anaesthetized and TC71 and TC32 cells (5 × 105 cells in 50 μl of Matri-
gel) expressing luciferase were implanted by intratibial injection 
as previously described (59). Briefly, the skin of the knee joint was 
prepped with alternating povidone iodine scrubs and 70% isopropyl 
at room temperature at a concentration of 500 to 1,000 μg siRNA/kg 
per injection (each mouse received 100 μl of DOPC-siRNA-PBS solu-
tion by the intraperitoneal route).
Xenograft tumor studies. Four- to six-week-old female NU/J mice 
were purchased from Jackson Laboratories and housed under patho-
gen-free conditions. When used in a power calculation, our sample 
size predetermination experiments indicated that 5 mice per group 
can identify the expected effect of SA1 depletion on tumor size and 
weight (P < 0.05) with 90% power. Animals were randomly divided 
into different groups. Dox-inducible BUC cells T24 and UC3 (5 × 105) 
Figure 9. SA1 depletion sensitizes SA2-mutated tumors to the treatment of the PARP inhibitor BMN-673. (A–F) Kaplan-Meier survival curves (A and D), indi-
vidual tumor growth curves (B and E), and representative bioluminescent images (C and F) of xenograft tumors derived from orthotopically implanted TC32 (A–C) 
or UC3 (D–F) cells. Once tumor was established, mice were randomly divided into 4 groups and then treated with DMSO and control siRNA, siSA1 nanoliposome 
(twice weekly), BMN-673 (daily), or a combination of siSA1-DOPC nanoliposome and BMN-673. (G) Quantification of SA1 KD efficiency, cell proliferation (Ki-67 
staining), and apoptosis (cleaved caspase-3 staining) in the xenografted tumor tissues described above. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, log-
rank Mantel-Cox test (A and D) and unpaired 2-tailed t test (G). Data are representative of 2 independent experiments and are presented as mean ± SD.
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percentage of positive cells (signal: 0 = no signal, 1 = weak signal, 2 = 
intermediate signal, and 3 = strong signal; percentage: 10%–100%). 
High expression of SA1 corresponded to a staining score of 201–300, 
and medium expression corresponded to a staining score of 101–200, 
whereas low expression corresponded to a staining score of 0–100. 
Slides were scanned using Pannoramic 250 Flash III (3DHISTECH 
Ltd.), and images were captured through Pannoramic Viewer software 
(3DHISTECH Ltd.).
Bioinformatic analysis. We extracted the most frequently mutated 
metabolic/housekeeping genes across human cancers by using the 
data obtained from the Broad Institute Cancer Cell Line Encyclope-
dia (CCLE; www.broadinstitute.org/ccle) and TCGA (61, 62), as pre-
viously described (12, 13, 63). To determine whether a mutated gene 
functions as a redundant housekeeping gene, we first analyzed its 
expression profiles in tumor and normal tissues as well as its gener-
al functions from the literature. Second, we asked whether a known 
genetic interaction resulting in lethality was already documented in 
invertebrates or mice, using Saccharomyces Genome Database (SGD; 
https://www.yeastgenome.org/); WormBase (WB; https://worm-
base.org/#012-34-5); FlyBase (FB; http://flybase.org/); and Mouse 
Genome Informatics (MGI; https://www.google.com/search?q=Mo
use+Genome+Informatics&ie=utf-8&oe=utf-8&client=firefox-b-1). 
Third, we searched for available cell lines and small molecules to test 
the redundancy hypothesis. Finally, we searched MGI to determine 
whether knockout of the drug-target homologue is deleterious, to pre-
dict how well a potential drug would be tolerated.
For deep sequencing, TC71 and TC32 cells were treated with or 
without Dox for 72 hours. Then total mRNA was isolated using the 
Direct-zol RNA Extraction Kit (Zymo Research) and submitted for 
deep sequencing. FastQC was adopted first to examine RNA-seq qual-
ity, followed by a step to map high-quality sequences to the human 
genome (hg19, UCSC Genome Browser, https://genome.ucsc.edu/) 
with STAR, an RNA-seq aligner (64). The featureCounts (65) was used 
to assign uniquely mapped reads to genes according to UCSC refGene 
(hg19). After normalizing the gene expression based on trimmed 
mean of M values, we employed EdgeR (66) to perform differential 
expression analysis with comparison between no treatment (NT) 
and KD for each cell line, TC32 and TC71, respectively. If 1 gene had 
an FDR-adjusted P value of less than 0.05 and an absolute value of 
fold change (FC) (log scale with base 2) larger than 1.75, the gene was 
identified as a differentially expressed gene (DEG). DEGs with higher 
expression levels, whose average counts per million (CPM) were larger 
than 2 for either NT or KD samples, were collected for DAVID func-
tional annotation analysis (67). An HRD signature consisting of 230 
DEGs was obtained as previously described (68). The HRD score was 
defined as the sum of all RNA expression in the HRD signature. Both 
raw and processed data were deposited in the NCBI’s Gene Expression 
Omnibus database (GEO GSE111004).
Statistics. Each experiment was repeated 3 times or more. Unless 
otherwise noted, data are presented as mean ± SD, and Student’s t 
test (unpaired, 2 tailed) was used to compare 2 groups of independent 
samples. In an unpaired t test, we assumed equal variance and that no 
samples were excluded from the analysis. One-way ANOVA followed 
by Tukey’s t test was conducted to compare 3 or more groups of inde-
pendent samples. Survival analysis was done using the Kaplan-Meier 
method, as assessed using a log-rank Mantel-Cox test. P < 0.05 was 
considered statistically significant.
alcohol wipes. Mouse tibias were predrilled with a 26-gauge needle 
and x-rayed to validate needle placement. Then luciferase-express-
ing EWS cells were injected with a glass Hamilton syringe and 45° 
bevel 26-gauge needle. For the orthotopic BUC mouse model, the 
NU/J mice were anesthetized with 2.5% isoflurane and cells were 
implanted following the procedures, as described previously (60). A 
24-gauge Teflon-coated catheter was introduced into the lumen of 
the bladder through the urethra. Urine was evacuated from the blad-
der by mild pressure on the abdomen. RT4 and UC3 cells (0.5 × 106) 
expressing luciferase in a 50 μl suspension of serum-free RPMI-1640 
medium were then injected into the bladder. To prevent voiding of 
UC3 cells, the catheter was held in place for at least 45 minutes with 
the injection syringe attached. The catheter was removed before 
the mouse recovered from anesthesia. Tumors were monitored by 
the IVIS system after luciferin injection for 15 minutes. After initial 
establishment of tumor (100 mm3 for subcutaneous implants and 2 
× 108 photons/s total flux for orthotopic implants), mice were treated 
with 1 μg/ml Dox in drinking water for 3 to 6 weeks. The Dox water 
was changed every other day.
For xenograft tumor studies using DOPC-siRNA and PARP inhibi-
tor BMN-673, mice bearing orthotopically implanted EWS or bladder 
tumors were randomized to 4 groups (the number of mice in each group 
is indicated in Figure 9 and Supplemental Figure 9) and received the 
following treatments: (a) DMSO and DOPC-control siRNA; (b) DMSO 
and DOPC-SA1 siRNA alone; (c) BMN-673 and DOPC-control siRNA; 
and (d) DOPC-SA1 siRNA plus BMN-673. DOPC-siRNA-PBS solution 
was administered twice weekly by intraperitoneal injection, whereas 
the inhibitor BMN-673 (0.33 mg/kg) was administered once daily by 
oral gavage. Tumors were monitored by the IVIS system twice a week. 
Body weights were recorded every week. Mice were euthanized when 
they met the institutional euthanasia criteria for tumor size and overall 
health condition. Tumors were removed, photographed, and weighed. 
The freshly dissected tumor tissues were fixed in 10% buffered for-
malin overnight, transferred to 70% ethanol, embedded in paraffin, 
sectioned, and stained with H&E and indicated antibodies.
Immunohistochemistry and human bladder tissue microarray. BUC 
tissue microarray (BL2081) was purchased from Biomax, including 
192 bladder tumor samples and 16 normal adjacent tissue samples. 
Tissue samples were deparaffinized and rehydrated. Antigen was 
retrieved using 0.01 M sodium citrate buffer (pH 6.0) at a subboiling 
temperature for 10 minutes after boiling in a microwave oven. To block 
endogenous peroxidase activity, the sections were incubated with 3% 
hydrogen peroxide for 10 minutes. After 1 hour of preincubation in 5% 
normal goat serum to prevent nonspecific staining, the samples were 
incubated with antibodies against SA1 (catalog HPA035015, Sigma-
Aldrich), SA2 (catalog HPA002857, Sigma-Aldrich), SA3 (catalog 
HPA049106, Sigma-Aldrich), Ki-67 (catalog D3B5, Cell Signaling), 
or cleaved caspase-3 (catalog 5A1E, Cell Signaling) at 4°C overnight. 
The sections were incubated with a biotinylated secondary antibody 
(4Plus biotinylated anti-mouse or anti-rabbit IgG, Biocare) and then 
incubated with avidin-biotin peroxidase complex solution and devel-
oped using a DAB substrate kit (550880, BD Biosciences) according 
to the manufacturer’s protocol. Counterstaining color was carried out 
using Harris Modified Hematoxylin. The BUC tissue microarrays were 
reviewed and scored in a blinded manner for staining intensity. Signals 
of immunohistochemistry data in tumor cells were visually quantified 
using a scoring system from 0 to 3, multiplied intensity of signal, and 
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